Pharmaceuticals

Oral Biologics & Biosimilar Drugs Market Analysis Covering Growth Drivers And Future Outlook

May 1, 2026May 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Oral Biologics & Biosimilar Drugs Market Between 2026 And 2030?

The market size for oral biologics & biosimilar drugs has experienced exponential growth in recent years. It is anticipated to rise from $8.6 billion in 2025 to $10.41 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 21.0%. This historical expansion can be linked to factors such as the restricted availability of oral biologics, a dependence on injectable biologics, the increasing prevalence of autoimmune and inflammatory diseases, a heightened patient desire for cost-effective treatments, and the initial approvals of monoclonal antibody drugs.

The oral biologics & biosimilar drugs market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $17.17 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.3%. Factors contributing to this expansion during the forecast timeframe include the creation of advanced oral biologics, the broadening of the biosimilar development pipeline, a rise in the uptake of combination treatments, the proliferation of digital health solutions for patient oversight, and enhanced regulatory backing for biosimilar authorizations. Key developments expected over the forecast period encompass an increasing embrace of oral biologics and biosimilar medicines, a heightened emphasis on managing chronic illnesses with biologics, the widening of hospital and retail pharmacy distribution networks, improved patient understanding and acceptance of biosimilars, and the creation of specific treatments for autoimmune and inflammatory conditions.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3792&type=smp

What Key Factors Are Shaping The Oral Biologics & Biosimilar Drugs Market Landscape?

The growing incidence of chronic diseases such as arthritis, asthma, and cancer is expected to serve as a major driver for the oral biologics and biosimilar market. Factors like prolonged working hours, insufficient physical activity, and poor eating and drinking habits contribute to the rise of chronic conditions, and biologics are increasingly employed in their treatment. Biologics work by activating the immune system’s response against cancer cells, thereby aiding the immune system in eliminating them from the body. For instance, in May 2023, according to a United Nations article, by 2030 the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic disease is expected to reach about 60%. Therefore, the rise in the prevalence of chronic diseases is projected to boost the demand for biologics and biosimilars, consequently driving the oral biologics & biosimilar drugs market growth.

Which Segment Types Are Examined In The Oral Biologics & Biosimilar Drugs Market Segment Study?

The oral biologics & biosimilar drugs market covered in this report is segmented –

1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors

2) By Disease: Asthma, Crohn’s Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others

3) By Molecule Type: Proteins & Peptides, Monoclonal Antibodies, Other Molecule Types

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Lymphocyte Modulators: Fingolimod, Ocrelizumab, Natalizumab

2) By Interleukin Inhibitors: Ustekinumab, Secukinumab, Guselkumab

3) By Tumor Necrosis Factor-Alpha Inhibitors: Adalimumab, Certolizumab Pegol, Golimumab

Which Trends Are Impacting The Progress Of The Oral Biologics & Biosimilar Drugs Market?

Leading firms within the oral biologics and biosimilar markets are prioritizing advanced products, like incretin triagonists, aiming to improve patient results, boost drug effectiveness, and offer alternatives to current injectable treatments. Incretin triagonists are medications engineered to simultaneously stimulate three specific hormone receptors: GLP-1, GIP, and glucagon, critical for managing blood sugar levels, appetite control, and metabolic processes. As an example, in October 2024, Rani Therapeutics Holdings Inc., a US-based biotechnology firm, published novel preclinical pharmacokinetic findings demonstrating the efficacy of transenteric delivery for a GLP-1 incretin triagonist. Their product, the RaniPill, an oral capsule developed to administer biologics that typically necessitate injections, effectively delivered an incretin triagonist aimed at GLP-1, GIP, and glucagon receptors, which are crucial targets in addressing obesity. The RaniPill exhibited efficacy comparable to subcutaneous injections, providing a needle-free option characterized by high bioavailability and adaptable dosing, thereby positioning it as a significant potential solution for new obesity medications.

Which Players Are Part Of The Competitive Landscape Of The Oral Biologics & Biosimilar Drugs Market?

Major companies operating in the oral biologics & biosimilar drugs market are Novartis International AG, Rani Therapeutics Holdings Inc., Eli Lilly and Company, AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals Inc., BiosanaPharma, Entera Bio Ltd., Allergan plc, Emisphere Technologies Inc., Enteris BioPharma Inc., Chiasma Inc., Allena Pharmaceuticals Inc., Gelgen Corporation, 3SBio Inc., Innovent Biologics Inc., GlaxoSmithKline PLC, Concord Biotech Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., Allergan Pharmaceuticals International Limited, Mylan N.V., Pfizer Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd.

Get The Full Oral Biologics & Biosimilar Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilar-drug-global-market-report

Where Is The Oral Biologics & Biosimilar Drugs Market Most Concentrated Geographically?

North America was the largest region in the oral biologics and biosimilar drugs market in 2025. The Middle East is expected to be the fastest growing region in the oral biologics & biosimilar drugs market report during the forecast period. The regions covered in the oral biologics & biosimilar drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Oral Biologics & Biosimilar Drugs Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilar-drug-global-market-report

Browse Through More Reports Similar to the Global Oral Biologics & Biosimilar Drugs Market 2026, By The Business Research Company

Dental Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/dental-services-global-market-report

Dental Practice Management Market Report 2026

https://www.thebusinessresearchcompany.com/report/dental-practice-management-global-market-report

Dental X Ray Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/dental-x-ray-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795